Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Dexamethasone

Bortezomib

Dexamethasone acetate

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Plitidepsin will be administered as a 3-hour (h) intravenous (i.v.) infusion on Day (D) 1 and 15, every four weeks (q4wk).

Bortezomib will be administered as a subcutaneous (s.c.) injection on D1, 4, 8 and 11, q4wk, for a maximum of eight cycles.

Dexamethasone will be taken orally on D1, 8, 15 and 22, q4wk

Plitidepsin

Study of Plitidepsin (Aplidin®) to determine the recommended dose (RD) of plitidepsin in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma.

Phase I Multicenter, Open-label, Dose-escalating Clinical and Pharmacokinetic Trial of Plitidepsin (Aplidin®) to determine the recommended dose (RD) of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM), to determine the efficacy of the combination plitidepsin/bortezomib/dexamethasone, to evaluate the safety and tolerability of the combination in patients with relapsing and/or refractory MM and to study the pharmacokinetics (PK) and pharmacodynamics (PDy) of plitidepsin in combination with bortezomib and dexamethasone.

Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

Phase I Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

To determine the recommended dose (RD) of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma (MM). To define the RD, patients will be evaluated for DLTs during the first 28-day cycle. The RD will be the highest DL at which fewer than two out of six (33%) of evaluable patients experience a DLT during the first 28-day cycle.

DLTs were defined as:

Hematological Toxicity

* Grade 3/4 neutropenia associated with fever or lasting\>7 days related to the study treatment
* Grade 3/4 thrombocytopenia accompanied by grade 3/4 hemorrhage
* Extensive bone marrow (BM) infiltration, DLT was defined as grade 4 thrombocytopenia with grade 3/4 hemorrhage or grade 4 neutropenia lasting \>7 days or with fever Non-hematological Toxicity
* Grade 3/4 nausea and vomiting refractory to antiemetic therapy
* Grade≥3 muscular Adverse events (AE) (myalgia, muscular weakness, muscle cramps, myopathy)
* Grade≥3 alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) lasting more than 1 week
* Grade≥3 bilirubin increase
* Grade≥3 creatine phosphokinase (CPK) increase
* Cardiac toxicity

  * Symptomatic or treatment-requiring grade ≥1 cardiac arrhythmia related to plitidepsin
  * Grade≥1 left ventricular systolic dysfunction related to plitidepsin
* Neuropathic pain and peripheral sensory neuropathy related to BTZ

Stringent complete response (sCR) normal Free Light Chains (FLC) ratio. No clonal cells Complete response (CR) no serum/urine M-protein, no evidence of soft tissue plasmacytoma. \<5% clonal plasma cells Very good partial response (VGPR) serum and urine M-protein detectable but not electrophoresis or \>90% reduction in serum M-protein and urine M-protein \<100 mg/24h Partial response (PR) ≥50% reduction in serum M-protein and 90% reduction in 24h urine M-protein or to \<200 mg/24h. 50% reduction in size of any soft tissue plasmacytomas Minor response (MR) 25%-49% reduction of serum M-protein and 50-89% reduction of 24h urine M-protein. 25-49% reduction in size of soft tissue plasmacytomas. No increase in size or number of bone lesions Stable disease (SD) No sCR, CR, VGPR, PR, MR or PD Progressive disease (PD) 25% increase from the lowest value: serum M-protein, urine M-protein, BM plasma cell. Increase in size, new bone lesions, soft tissue plasmacytomas or serum calcium \>11.5 mg/dL

Overall response rate (ORR), including stringent complete response (sCR), complete response (CR), very good partial response (VGPR) and partial response (PR) according to the International Myeloma Working Group (IMWG) criteria

Duration of response (DR) was analyzed for all patients in whom a response had been observed and was calculated from the date of the first documentation of response to the date of PD or further therapy or death

Time to progression (TTP) was calculated from the date of the first infusion to the date of documented PD or death due to PD.

Progression-free survival (PFS) was calculated from the date of the first infusion to the date of documented PD or death (regardless of the reason), whichever comes first

Event-free survival (EFS) was calculated from the date of first infusion to the date of documented PD or death, but could include additional events besides death and PD that were considered of importance

PharmaMar

Patients received plitidepsin 4 mg/m2 and BTZ 1 mg/m2 and DXM 40 mg. DXM was administered at least one hour before the start of plitidepsin infusion, and BTZ was administered one minute after the end of the plitidepsin infusion. Patients received a maximum of eight treatment cycles

Plitidepsin (4 mg/m2)+BTZ (1 mg/m2)+DXM (40 mg)

Patients received plitidepsin 4 mg/m2 and BTZ 1.3 mg/m2 and DXM 40 mg. DXM was administered at least one hour before the start of plitidepsin infusion, and BTZ was administered one minute after the end of the plitidepsin infusion. Patients received a maximum of eight treatment cycles

Plitidepsin (4 mg/m2)+BTZ (1.3 mg/m2)+DXM (40 mg)

Patients received plitidepsin 5 mg/m2 and BTZ 1.3 mg/m2 and DXM 40 mg. DXM was administered at least one hour before the start of plitidepsin infusion, and BTZ was administered one minute after the end of the plitidepsin infusion. Patients received a maximum of eight treatment cycles

Plitidepsin (5 mg/m2)+BTZ (1.3 mg/m2)+DXM (40 mg)

Total

Age, Categorical

Age, Continuous

Sex: Female, Male

Race/Ethnicity, Customized

ECOG PS, Eastern Cooperative Oncology Group performance status PS 0 Fully active able to carry on all pre-disease performance without restriction PS 1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature PS 2 Ambulatory and capable of all selfcare but unable to carry out any work activities up and about more than 50% of waking hours PS 3 Capable of only limited selfcare confined to bed or chair more than 50% of waking hours PS 4 Completely disabled cannot carry on any selfcare; totally confined to bed or chair PS 5 Dead

ECOG PS

Multiple myeloma type at diagnosis

Stage I: small number of myeloma cells. All are present:

* Hemoglobin \>100 g/L
* Blood calcium \<2.8 mmol/L
* No areas of bone damage or a solitary plasmacytoma of the bone
* Immunoglobulin G (IgG) \<50 g/L
* Immunoglobulin A (IgA) \<30 g/L
* Urine M-protein \<4 g

Stage II: Moderate number of myeloma cells. The features are between stage 1 and 3

Stage III: Large number of myeloma cells. One/more are present:

* Hemoglobin \<85 g/L
* Blood calcium \>2.8 mmol/L
* Several areas of bone damage
* IgG \>70 g/L
* IgA \>50 g/L
* Urine M-protein \>12 g

Durie-Salmon stage at diagnosis

Stage I: small number of myeloma cells. All are present:

* Hemoglobin more than 100 g/L
* Blood calcium less than 2.8 mmol/L
* No areas of bone damage or a solitary plasmacytoma of the bone
* IgG less than 50 g/L
* IgA less than 30 g/L
* Urine M-protein less than 4 g

Stage II: Moderate number of myeloma cells. The features are between stage 1 and 3

Stage III: Large number of myeloma cells. One/more are present:

* Hemoglobin less than 85 g/L
* Blood calcium more than 2.8 mmol/L
* Several areas of bone damage
* IgG more than 70 g/L
* IgA more than 50 g/L
* Urine M-protein more than 12 g

The stages of multiple myeloma are further divided according to creatinine level in the blood, which shows how well the kidneys are working.

Substage A: Kidney function is normal. Creatinine level is less than 180 µmol/L.

Substage B: Kidney function is abnormal. Creatinine level is 180 µmol/L or more.

Durie-Salmon subclassification at diagnosis

The International Staging System uses the results of 2 blood tests: albumin and beta-2-microglobulin level.

Stage 1: Beta-2-microglobulin level less than 3.5 mg/L and albumin level more equal than 35 g/L.

Stage 2: Beta-2-microglobulin level less than 3.5 mg/L and Albumin level less than 35 g/L or beta-2-microglobulin level is more than 3.5 mg/L but less than 5.5 mg/L and any albumin level.

Stage 3: Beta-2-microglobulin is 5.5 mg/L or more and any albumin level.

International Staging System at diagnosis

Disease status with respect to last prior therapy

CR, complete response; PD, progressive disease; PR, partial response; RD, recommended dose; SD, stable disease; UK, unknown; VGPR, very good partial response.

Best response to last prior anticancer therapy

Weight

Body surface area

Time from diagnosis to first infusion

Time from last progressive disease to first infusion

Lines of prior chemotherapy

Agents of prior chemotherapy

Pharma Mar S.A.

All participants who received at least 1 dose of plitidepsin as a 3-hour i.v. infusion on Days 1 and 15 in combination with BTZ administered s.c. on Days 1, 4, 8 and 11, and DXM orally on Days 1, 8, 15 and 22 q4wk in patients with relapsed and/or refractory MM

All Participants

Participants who received at least 1 dose study treatment

Recommended Dose of Plitidepsin in Combination With Bortezomib and Dexamethasone

Recommended Dose of Bortezomib in Combination With Plitidepsin and Dexamethasone

Recommended Dose of Dexamethasone in Combination With Plitidepsin and Bortezomib

Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)

Response According to International Myeloma Working Group Criteria

Overall Response Rate

Duration of Response

Time to Progression

At 3 months

At 6 months

At 12 months

Time to Progression Rates

Progression-free Survival

Progression-free Survival Rates

Event-free Survival

Event-free Survival Rates

Cohort 1: Dose Level 1

Cohort 2: Dose Level 2

Cohort 3: Dose Level 3

Lymphoma

Lymphoma, T-Cell

Lymphoma, T-Cell, Peripheral

Immunoblastic Lymphadenopathy

Lymphadenopathy

Lymphatic Diseases

Lymphoma, Non-Hodgkin

Lymphosarcoma

Peripheral T-cell Lymphoma

Angioimmunoblastic T-cell Lymphoma

Angioimmunoblastic Lymphadenopathy With Dysproteinemia

plitidepsin

Prospective, multicenter, phase II clinical trial to determine the efficacy of plitidepsin in patients with relapsed/refractory (R/R) angioimmunoblastic Tcell lymphoma (AITL).This is an international, multicenter study (with approximately 17 investigative sites).

Prospective, multicenter, phase II clinical trial to determine the efficacy of plitidepsin in patients with relapsed/refractory (R/R) AITL. The primary endpoint will be overall response rate (ORR) according to the Lugano classification response criteria per independent review.

Medical specialists (radiologists and hematologists) who are directly involved in the care of patients with AITL (but are not participating in this trial as investigators) will review all efficacy data (including radiological assessments, bone marrow biopsies) and will assign the best response and the date of objective response or progression/censoring according to their independent evaluation.

Central pathological review of each patient's original diagnosis report(s) will be required before inclusion.

Two futility analyses of the primary endpoint (ORR according to the Lugano classification criteria and per Independent Review Committee (IRC)) are planned around six months after approximately 25% and 50% of eligible patients (i.e., 15 and 30 patients respectively with AITL confirmed by central pathological review) have been treated. Two or less responders out of 15 patients or seven or less responders out of 30 patients, according to boundaries and sample size assumptions, will mean that the alternative hypothesis could be rejected, and thus recruitment might be stopped at the time of the first or second futility analysis, respectively. Otherwise, accrual will continue to 60 patients with AITL confirmed by central pathological review. This decision will be taken at the time by an Independent Data Monitoring Committee (IDMC). The IDMC, which will include specialists in peripheral T-cell lymphomas (PTCL) supported by a medical statistician, will review data provided by the Investigators, the IRC efficacy assessments and safety information and will advise whether the study should continue. Recruitment can continue during the review period.

If there are 19 or more responders of 60 patients, the efficacy of plitidepsin will be considered as clinically relevant in AITL patients.

Central pathological review will be conducted by experienced pathologists appointed by the Sponsor and available to the investigative sites for consultation about AITL diagnosis confirmation. Central pathological review is required for (a) local histopathology reports prior to patient treatment, and (b) tumor samples before each futility analysis and at the end of the study.

The central laboratory pathologists will be responsible for (a) approving patient inclusion on the basis of investigative site pathology reports provided during screening, (b) analyzing tumor biopsies (initial diagnosis and/or relapses) to confirm the AITL diagnosis, and (c) analyzing blood samples to identify plasma biomarkers and extract DNA.

Tumor samples (initial diagnosis and relapses) are required for central review to confirm AITL diagnosis but not to approve inclusion. Archived tissue samples of representative tumors must be sent for central review and biomarker analysis. If the diagnosis biopsy is not available (because the patient was diagnosed at another site, for example), the most recent representative biopsy (relapse and/or progression) will be used. Submitting both, however, is strongly recommended. Tumor blocks will be returned to the centers.

A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

A Phase II Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

The study protocol established that the analysis of the primary endpoint should have been done once a total of 60 patients have received plitidepsin, with two futility analyses planned after the inclusion of approximately 15 and 30 patients, respectively. However, only a total of 14 patients were included, of whom 13 were treated, and 12 were evaluable for the primary efficacy endpoint (ORR per IRC in the "Per Protocol Patients" population). As a result of slow patient accrual, the study was closed before reaching the target enrollment of 15 patients for the first futility analysis, and the primary endpoint (ORR according to the Lugano classification criteria and per IRC) was not assessed.

CI, confidence interval; CR, complete response; NE, not evaluable; ORR, overall response rate; PD, disease progression; PR, partial response; SD, stable disease.

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

One patient was never treated with plitidepsin and was excluded from the analysis of safety.

Plitidepsin was administered i.v. as a 1-hour infusion (fixed rate) via central or peripheral venous catheter. Patients received plitidepsin at a starting dose of 3.2 mg/m2 on Day 1, 8 and 15 every four weeks (q4wk). A 1-day window is allowed for plitidepsin administration. A cycle is defined as a fourweek period. A 1-day window was allowed for plitidepsin administration.

White

Hispanolatin

PS 0

PS 1

PS 2

III-A

III-B

IV-A

IV-B

Stages:

I cancer in a single region, usually one lymph node and the surrounding area. No outward symptoms II cancer in 2 separate regions, an affected lymph node or lymphatic organ and a 2nd affected area. Both affected areas are confined to one side of the diaphragm III cancer has spread to both sides of the diaphragm, including one organ or area near the lymph nodes or the spleen IV disseminated involvement of one/more extralymphatic organs A/B the absence of constitutional B-type symptoms is denoted by adding an A to stage; the presence adding a B

Ann Arbor stage

Extranodal disease at diagnosis

Bulky lesion at diagnosis

Low risk (0-1 risk factors)

Low-intermediate risk (2 risk factors)

High-intermediate risk (3 risk factors)

High risk (4-5 risk factors)

International Prognostic Index score at diagnosis

Group 1 (no adverse factors)

Group 2 (1 risk factor)

Group 4 (3-4 risk factors)

Prognostic index for peripheral T-cell lymphoma at diagnosis

Low-risk group

High-risk group

Prognostic index for angioimmunoblastic T-cell lymphoma score at diagnosis

International prognostic index score at current disease

Group 3 (2 risk factors)

Prognostic index for peripheral T-cell lymphoma at current disease

Prognostic index for angioimmunoblastic T-cell lymphoma score at current disease

1 line

2 lines

3 lines

4 lines

5 lines

Prior anticancer therapy lines

CR, complete response; PD, disease progression; PR, partial response; SD, stable disease; UK, unknown

Best response to last prior therapy

Allogenic stem cell transplantation

Autologous stem cell transplantation

Prior stem cell transplantation

Height

Body Surface Area

Time from diagnosis to first plitidepsin infusion

Time from last progressive disease to infusion

Time to progressions to last anticancer therapy

On 14May18, Sponsor informed to the sites and IPs its decision to close the recruitment. Study was terminated before reaching the target enrollment due to slow patient accrual and the negative opinion of the EMA-refusal of the mark. auth. plitidepsin

Clinical Developtment, Department of PharmaMar´s Oncology., Business Unit.

Justification: The study was closed before reaching the target enrollment of 15 patients for the first futility analysis, and the primary endpoint (ORR according to the Lugano classification criteria and per IRC) was not assessed.

Overall Response Rate by the Lugano Classification Per Independent Review Assessment

A patient was never treated with plitidepsin. A patient due to lack of AITL diagnosis confirmation

Overall Response Rate by Investigator's Assessment - Per Protocol Patients Population

Overall Study

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Adenocarcinoma

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Androgens

Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.

Aplidin (plitidepsin)

Celestia Higano, M.D.

Maha Hussain, M.D.

This is a study to test the safety and efficacy of an investigational chemotherapy agent in patients with advanced prostate cancer. Subjects who meet all entry criteria and have signed the informed consent will be enrolled in the study. Participants will be required to attend regular clinic visits to receive study medication and have their status monitored. A detailed explanation can be provided by the investigator conducting the study.

Prostate cancer is the most common non-cutaneous cancer diagnosed in men in the United States. The majority of deaths occur in men with androgen-independent prostate cancer \[AIPC\]. Although 80% of men with advanced cancer will initially respond to androgen ablation with disease regression or stabilization, their malignancies become resistant to such therapy.

A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer

A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..

Patients with an objective tumor response (complete response \[CR\] or partial response \[PR\]) per Response Evaluation Criteria In Solid Tumors Criteria (RECIST), See Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16.

To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after 2 previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.

PFS defined as time from the first day of study treatment to the day of a negative outcome (progression according to RECIST (Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. New Guidelines to Evaluate the Response to Treatment in Solid Tumors. J Natl Cancer Inst 2000; 92:205-16) or death) or last contact. If any patient is lost to follow up before disease progression, the PFS will be censored at the date of the last tumor assessment. If there are no tumor assessments the patient will be censored at the first drug administration date.

To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.

Survival is measured from the first day of study treatment to death or day of their last follow-up

To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.

Expressed as a change in pain intensity according to the pain intensity score on the 100 mm VAS (Visual Analogue Scale) and/or change in analgesic (morphine-equivalent mg) requirements after a pain stabilization period of 2-7 days

Visual Analogue Scale (VAS), expressed in the pain intensity score on the 100 mm VAS scale (0=least possible pain to 100=worst possible pain)

To assess the antitumor activity of plitidepsin given intravenously over 3-hours every two weeks in patients with castrate metastatic adenocarcinoma of the prostate that have relapsed or progressed after two previous lines of systemic therapy, considering biological agents or chemotherapy as systemic therapy and taking into account that patients must have received prior docetaxel-based chemotherapy.

It was calculated as (nadir value-baseline value)/(nadir date-baseline date). Modifications in the slope of PSA changes before and after the start of treatment with Aplidin will also be explored.

Aplidin (Plitidepsin)

Aplidin (plitidepsin): Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma	NCT02100657	Multiple Myelom...	Plitidepsin Bortezomib Dexamethasone	18 Years -	PharmaMar
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma	NCT03070964	Lymphoma	plitidepsin	18 Years -	PharmaMar
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer	NCT00780975	Prostate Cancer	Aplidin (plitid...	18 Years -	PharmaMar
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma	NCT00229203	Multiple Myelom...	Plitidepsin	18 Years -	PharmaMar
A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma	NCT00229203	Multiple Myelom...	Plitidepsin	18 Years -	PharmaMar
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas	NCT00788099	Advanced Solid ... Lymphomas	Plitidepsin and... Gemcitabine and...	18 Years -	PharmaMar
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or Lymphomas	NCT00788099	Advanced Solid ... Lymphomas	Plitidepsin and... Gemcitabine and...	18 Years -	PharmaMar
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer	NCT00780975	Prostate Cancer	Aplidin (plitid...	18 Years -	PharmaMar
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide	NCT03117361	Multiple Myelom...	plitidepsin Bortezomib Dexamethasone	18 Years -	PharmaMar

Spots Global Cancer Trial Database for plitidepsin

Every month we try and update this database with for plitidepsin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for plitidepsin

Every month we try and update this database with for plitidepsin cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for plitidepsin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.